Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age18+
SponsorBiohaven Pharmaceuticals, Inc.
About this trial
The purpose of this expanded access protocol is to provide access to the investigational drug troriluzole in patients with spinocerebellar ataxia (SCA).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient has a confirmed diagnosis of Spinocerebellar Ataxia (SCA), defined as either clinical evidence supporting diagnosis OR confirmed genotypic diagnosis.
Adequate hepatic function.
Disqualifiers
Patient is known to have acute or chronic liver disease that is clinically significant in the judgement of the Physician.
Patient has a history of a clinically significant medical condition that would interfere with the patients ability to comply with the expanded access protocol or would place the patient at increased risk.
Trial design
Treatments tested in this trial
Troriluzole
DrugBHV-4157 140mg, 200mg or 280mg once daily by mouth.
Treatment groups
No treatment groups listed
Trial outcomes
This trial has no outcomes listed.Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov